Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches by Pagano, Livio et al.
Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria
and therapeutical approaches
Livio Pagano,1 Caterina G. Valentini,1 Sara Grammatico2 and Alessandro Pulsoni2
1Institute of Haematology, Catholic University, and 2Division of Haematology, Department of Cellular Biotechnologies and
Haematology, “Sapienza University”, Rome, Italy
Summary
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a
rare haematological malignancy derived from the precursors
of plamacytoid dendritic cells, with an aggressive clinical
course and high frequency of cutaneous and bone marrow
involvement. Neoplastic cells express CD4, CD43 (also ter-
med SPN), CD45RA and CD56 (also termed NCAM1), as
well as the plasmacytoid dendritic cell-associated antigens
CD123 (also termed IL3RA), BDCA-2 (also termed CD303,
CLEC4E) TCL1 and CTLA1 (also termed GZMB). The med-
ian survival is only a few months as the tumour exhibits a
progressive course despite initial response to chemotherapy.
The best modality of treatment remains to be defined. Gen-
erally, patients receive acute leukaemia-like induction,
according to acute myeloid leukaemia (AML)-type or acute
lymphoid leukaemia (ALL)-type regimens. The frequent neu-
romeningeal involvement indicates systematic pre-emptive
intrathecal chemotherapy in addition to intensive chemother-
apy. Allogeneic haematopoietic stem cell transplantation
(HSCT), particularly when performed in first remission, may
improve the survival. Preliminary data suggest a potential
role for immunomodulatory agents and novel targeted drugs.
Herein epidemiology, clinical manifestations, diagnosis and
management of BPDCN will be presented. In detail, this
review focuses on the therapeutic aspects of BPDCN, propos-
ing a treatment algorithm for the management of the disease,
including induction chemotherapy, allogeneic HSCT and
intrathecal prophylaxis at different steps of treatment,
according to compliance, biological and clinical characteris-
tics of patients.
Keywords: blastic plasmacytoid dendritic cell neoplasm,
acute leukaemia, chemotherapy, haematopoietic stem cell
transplantation, intrathecal prophylaxis.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a
rare, clinically aggressive haematological malignancy derived
from the precursors of plasmacytoid dendritic cells and char-
acterized by co-expression of CD4 and CD56 (also termed
NCAM1) without other lineage-specific markers (Chaperot
et al, 2001; Petrella et al, 2002). The nomenclature used to
describe this entity has evolved over the years as our under-
standing of the underlying biology has improved (Table I). It
was initially described in 1994 as agranular CD4+ natural
killer cell leukaemia due to its unique agranular morphology
and phenotype (CD4+, CD56+, CD15+ and CD3-) (Adachi
et al, 1994; Brody et al, 1995). Based on the blastic appear-
ance and CD56 expression, the term ‘blastic NK cell lym-
phoma’ was then used (Chan et al, 2001). Subsequently, the
term ‘agranular CD4+CD56+ haematodermic neoplasm/tu-
mour’ was coined based on the immunophenotype and the
predilection for skin involvement (Petrella et al, 2002). The
several synonyms and periodic name changes reflect the
uncertainty of the cell origin. However, following the discov-
ery and the confirmation that BPDCN derives from plasma-
cytoid dendritic cells (type 2 dendritic cells) (Willemze et al,
2002; Herling & Jones, 2007), the current nomenclature,
blastic plasmacytoid dendritic cell neoplasm, was chosen to
describe the entity in the 2008 World Health Organization
(WHO) classification of tumours of the haematopoietic and
lymphoid tissues, where it was recognized as a distinct dis-
ease and separately listed in the group of acute myeloid leu-
kaemia (AML) and related precursor neoplasms (Facchetti
et al, 2008) (Table I).
This review focuses on the clinical and, above all, the ther-
apeutic aspects of BPDCN, and proposes a treatment algo-
rithm for the management of the disease.
Epidemiology
There are no formal studies on the incidence of BPDCN in
the general population. In addition, the exact prevalence of
BPDCN is difficult to estimate due to the constantly chang-
ing nomenclature and lack of precise defining criteria prior
to the 2008 WHO classification (Facchetti et al, 2008). The
few available data reported that its overall incidence is extre-
mely low, accounting from 044% of all haematological
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malignancies (Bueno et al, 2004) to 07% of cutaneous lym-
phomas (Ng et al, 2006). However, cutaneous lymphoma
registries probably underestimate the true incidence of
BPDCN because a small but significant proportion of
patients present without skin lesions. Furthermore the leu-
kaemic form of disease is a rare phenomenon, representing
<1% of acute leukaemia cases (Jacob et al, 2003).
BPDCN has been described in all races and all geographic
locations. Predominantly males are affected, with a sex ratio
of 25:1. The disease usually occurs in elderly patients, with a
median age between 60 and 70 years (Feuillard et al, 2002;
Petrella et al, 2005), however, it can present at any age; pae-
diatric cases have also been reported, with a less aggressive
clinical course (Garnache-Ottou et al, 2007; Facchetti et al,
2009, 2016; Jegalian et al, 2010).
The aetiology of BPDCN is unknown. There are no docu-
mented environmental or hereditary genetic factors predis-
posing to the development of disease. BPDCN can occur as
an isolated disease or in the context of other haematologi-
cal neoplasms. Approximately 10–20% of patients have
a previous history of haematological malignancies includ-
ing myelodysplastic syndrome (MDS), chronic myeloid leu-
kaemia, chronic myelomonocytic leukaemia and AML
(Feuillard et al, 2002; Julia et al, 2013; Pagano et al, 2013). A
Gruppo Italiano Malattie Ematologiche dell’Adulto
(GIMEMA) study described four patients with a prior history
of MDS among a population of 43 cases (Pagano et al,
2013), and the French group described two cases of MDS
among 23 patients (Feuillard et al, 2002). The Hellenic Den-
dritic Cell Leukaemia Study Group reported two cases of sec-
ondary BPDCN among 22 patients (Tsagarakis et al, 2010).
The relationship between BPDCN and other myeloid malig-
nancies is not clearly elucidated. However, the association
with MDS and other myeloid neoplasms strengthens the
myeloid origin of the neoplastic clone.
Clinical features
In most patients BPDCN usually presents with cutaneous
lesions with or without bone marrow involvement (Feuil-
lard et al, 2002; Julia et al, 2014). In fact, isolated skin
lesions are frequently the first symptom leading patients to
seek medical advice, and without therapy, they rapidly dis-
seminate. Patients typically present with asymptomatic, soli-
tary or multiple skin lesions that can be variable in size
(from a few millimetres to 10 cm), shape and colour, and
can appear as nodules, plaques or bruise-like infiltrates. The
skin lesions can be associated with erythema, hyperpigmen-
tation, purpura or ulceration (Julia et al, 2013). Lym-
phadenopathy, splenomegaly and cytopenias due to bone
marrow involvement can be present at diagnosis or may
occur at disease progression. When bone marrow is
involved, the most common findings in the peripheral
blood are thrombocytopenia (78%), anaemia (65%) and
neutropenia (34%) (Pagano et al, 2013). Hyperleucocytosis
is infrequent, but the presence of blasts in the blood is
more commonly observed. Circulating malignant cells can
be detected by morphological review or flow cytometric
analysis of the peripheral blood. Morphologically, they
appear as monomorphic, poorly differentiated, intermediate-
sized blasts (Facchetti et al, 2008). Involvement of other
sites, including liver, tonsils, soft tissues, paranasal cavities,
lungs, eyes and central nervous system (CNS) have also
been reported (Feuillard et al, 2002; Tsagarakis et al, 2010;
Pagano et al, 2013; Feng et al, 2014; Martın-Martın et al,
2015). Of note, the incidence of neuromeningeal involve-
ment is quite frequent, ranging in the major studies from
4% to 9% of patients at diagnosis and from 17% to 33%
at relapse (Feuillard et al, 2002; Tsagarakis et al, 2010;
Pagano et al, 2013; Martın-Martın et al, 2015).
Patients presenting with a leukaemic picture in the
absence of cutaneous disease have also been described (Rauh
et al, 2012; Wang et al, 2012; Pagano et al, 2013). The
GIMEMA study described the largest number of patients
affected by BPDCN with leukaemic presentation, among
which 23% of cases had no cutaneous manifestations at diag-
nosis and only 2 patients developed skin lesions during the
progression of disease (Pagano et al, 2013).
Table I. Evolution of the nomenclature used to describe ‘Blastic
plasmacytoid dendritic cell neoplasm’.
Nomenclature References
CD4+/CD56+ acute monoblastic leukaemia Tauchi et al (1990)
Acute agranular CD4+ NK-cell leukaemia Brody et al (1995)
Cutaneous agranular CD2/CD4+/CD56+
lymphoma
Kameoka et al (1998)
Primary cutaneous CD4+/CD56+
haematolymphoid neoplasm
Petrella et al (1999)
Agranular CD4+/CD56+ blastic NK
leukaemia/lymphoma
Kimura et al (2001)
Blastic NK-cell lymphoma (WHO
classification)
Chan et al (2001)
DC2 precursor acute leukaemia Chaperot et al (2001)
CD4+/CD56+ acute leukaemia Feuillard et al (2002)
Agranular CD4+/CD56+ haematodermic
tumour
Petrella et al (2002)
Early plasmacytoid dendritic cell
leukaemia/lymphoma
Jacob et al (2003)
CD4+/CD56+ haematodermic neoplasia
(WHO-EORTC classification)
Willemze et al (2005)
DC2-related CD4+/CD56+ blastic
tumour of skin
Herling and Jones
(2007)
Blastic plasmacytoid dendritic cell
neoplasm in: Acute myeloid leukaemia
(AML) and related precursor
neoplasms (WHO classification)
Facchetti et al (2008)
WHO, World Health Organization; EORTC, European Organization
for Research and Treatment of Cancer.
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Immunophenotype and genetics
BPDCN usually exhibits a specific immunophenotype that
must be confirmed by either immunohistochemistry or by
flow cytometry, depending on the material available. The
diagnosis relies on the demonstration of CD4 and CD56 pos-
itivity by tumour cells, together with markers more restricted
to plasmacytoid dendritic cells [BDCA-2(also termed CD303,
CLEC4E), CD123 (also termed IL3RA), TCL1 (also termed
TCL1A)] and lack of expression of markers for B cells, T
cells, myeloid or monocytic cells, and NK cells (Table II)
(Facchetti, 2013; Facchetti et al, 2016). Exceptions include
CD5, CD7 and CD33, which may be positive in some cases,
and cytoplasmic CD3, which has been rarely reported using
polyclonal antibodies (Facchetti et al, 2016).
The highly specific marker BDCA-2/CD303, as well as
other plasmacytoid dendritic cell-associated antigens (CD2AP
and above all TCL1), might be of great support to definitely
establish the diagnosis and to exclude potential imitations of
BPDCN (Petrella et al, 2004; Garnache-Ottou et al, 2007;
Herling & Jones, 2007; Facchetti et al, 2008; Marafioti et al,
2008; Montes-Moreno et al, 2013). In particular, myeloid
sarcoma/AML, T-cell lymphoblastic leukaemia/lymphoma
(T-ALL/LBL), NK-cell lymphoma/leukaemia, and some
mature T-cell lymphomas/leukaemia should be excluded
through extensive immunophenotypic analysis (Table II).
Despite that, in some cases the diagnosis still remains a chal-
lenge, probably because of the lack of recurrent and specific
chromosomal abnormalities, its overlapping features with
other entities, and its heterogeneous clinical presentation
with multiple and variable tissue localizations. In particular,
a clear diagnosis can be difficult to achieve when blast cells
don’t completely fit the typical CD4+CD56+HLA-
DRhiCD123+lineage immunophenotypic profile. In fact, evi-
dence exists regarding a broad range of atypical phenotypic
profiles (Facchetti et al, 2003), including the absence of
CD56 (Kawai, 2005; Martın-Martın et al, 2015) and CD4
(Montes-Moreno et al, 2013). In addition, atypical cases with
aberrant expression of B, T or myeloid antigens have also
been described (Garnache-Ottou et al, 2005; Cota et al,
2010). Garnache-Ottou et al (2009) proposed a diagnostic
algorithm for establishing an immunophenotypic diagnosis
of BPDCN. The coexpression of CD4+, CD56+/, CD123+,
BDCA-2+ and/or BDAC-4+ and the absence of CD3-,
CD11c-, MPO- and CD79a- were diagnostic for BPDCN. If
CD123 expression is negative or when CD123 is positive but
cells don’t express BDCA-2 or BDCA-4, diagnosis of BPDCN
should not be considered (Garnache-Ottou et al, 2009). Julia
et al (2014) reported the immunohistochemical typing of 91
patients with BPDCN from the French Study Group on
Cutaneous Lymphomas. They identified five of the most
characteristic immunophenotypic markers, which included
CD4, CD56, CD123, CD303 and TCL1. The contemporary
expression of all markers was observed in only 46% of
patients, but the expression of 4 markers was sufficient for
reliable diagnosis (Julia et al, 2014). Finally, Facchetti (2013)
reviewed the antigen expression on formalin-fixed, paraffin-
embedded sections in a series of more than 300 published
cases, suggesting that, in addition to CD4 and CD56, CD123
and TCL1 are the most reliable and useful markers to con-
firm or to exclude BPDCN diagnosis.
Recently, Martın-Martın et al (2015) described a series of
46 patients classified into three maturation-associated sub-
groups on immunophenotypic grounds, investigating
whether the immunophenotypic features utilized for diagno-
sis can also correlate with the clinico-biological and prognos-
tic characteristics of the disease. They showed that blasts
from cases with an immature plasmacytoid dendritic cell
phenotype exhibit an uncommon CD56- phenotype, coexist-
ing with CD34+ non-tumour cells, typically in the absence of
extramedullary disease at presentation. Conversely, patients
with a more mature blast cell phenotype more frequently dis-
played skin and extramedullary involvement and spread into
secondary lymphoid tissues. The authors concluded that
tumour cells from BPDCN might show a highly variable pro-
file of maturation, which translates into a heterogeneous clin-
ical behaviour ranging from that of acute leukaemia to
peripheral mature lymphomas, which may also lead to vari-
able diagnosis and treatment (Martın-Martın et al, 2015).
In conclusion, at present, although no consensus has been
established with regard to a minimal phenotype to diagnose
BPDCN, a confident diagnosis can be made when four anti-
gens among CD4, CD56, CD123, TCL1 and BDCA-2/CD303
are expressed by neoplastic cells (Alayed et al, 2013; Boiocchi
et al, 2013; Facchetti, 2013; Julia et al, 2014). According to
the WHO, neoplasms which share some but not all
immunophenotypic features of BPDCN may be better classi-
fied as ‘acute leukaemia of ambiguous lineage’ (Facchetti
et al, 2008).
Most part of BPDCN present genetic abnormalities, even
if there is no single cytogenetic change that is typical or diag-
nostic. A few studies have focused on BPDCN genetics, doc-
umenting a complex karyotype with deletions on
chromosomes 5q21 or 5q34 (72%), 12p13 (64%), 13q13-q21
(64%), 6q23-qter (50%), 15q (43%) and 9 (28%) and spo-
radic genetic alterations affecting the RB1, LATS2, CDKN1B,
CDKN2A and TP53 genes (Leroux et al, 2002; Petrella et al,
2005; Facchetti et al, 2009). The biallelic loss of 9p213 was
associated with a poor prognosis (Leroux et al, 2002). Molec-
ular studies have also been performed; mutations in TET2
and TP53 were reported in 54% and 38% of cases among 13
patients analysed, respectively (Jardin et al, 2011). Moreover
Dijkman et al (2007) identified overexpression of the onco-
genes HES6, RUNX2 and FLT3 independently of genomic
amplification. NPM1 mutations have not been reported,
while FLT3ITD internal tandem duplication (ITD) mutations
can be present in a subset of patients (Pagano et al, 2013).
In addition to classical cytogenetic analysis, BPDCN has
been assessed by array comparative genomic hybridization
(CGH) analyses (Lucioni et al, 2011; Oiso et al, 2012;
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Stenzinger et al, 2014), which confirm that loss of genetic
material is much more frequent than presence of additional
genetic material. Furthermore, proteins that regulate cell
cycle are preferentially targeted. CDKN2A/CDKN2B on
9p213 is frequently lost. Other frequently deleted regions
include 13q131-q143 (RB1), 12p132-p131 (CDKN1B),
13q11-q12 (LATS2), and 7p122 (IKZF1) (Jardin et al, 2009;
Lucioni et al, 2011).
More recently, Sapienza et al (2014) performed gene
expression profiling in 27 samples of BPDCN, detecting an
aberrant activation of the NF-kB pathway, concomitantly with
the up-regulation of two NF-kB targets (BCL2 and IRF4).
Altogether, these molecular data demonstrate that BPDCN
cells can carry multiple mutations that overlap with the
genetic abnormalities of myeloid and lymphoid neoplasms,
leading to the dysregulation of multiple pathways that may
serve as targets for therapeutic agents.
Treatment
The clinical course of BPDCN is aggressive, with a reported
median overall survival (OS) ranging from 12 to 16 months
(Feuillard et al, 2002; Petrella et al, 2005). Because of its low
incidence, prospective data are lacking and the few series
published so far rarely exceed 15 cases (Feuillard et al, 2002;
Dalle et al, 2010; Tsagarakis et al, 2010; Dietrich et al, 2011;
Lucioni et al, 2011; Hashikawa et al, 2012; Pemmaraju et al,
2012; Pagano et al, 2013; Martın-Martın et al, 2015)
(Table III). Moreover, no prognostic models are available to
tailor therapy to individual cases. Consequently, no standard-
ized therapeutic approach has been established yet and the
optimal therapy remains to be defined.
Conventional chemotherapy
In patients with isolated cutaneous disease at the onset, the
efficacy of skin-directed therapies, such as surgical excision,
focal radiation therapy and systemic steroids, has been evalu-
ated in several studies (Reimer et al, 2003; Dalle et al, 2010;
Li et al, 2011; Pileri et al, 2012). These approaches can be
initially effective and may lead to the complete resolution of
cutaneous lesions, but do not appear to provide a long-term
benefit. In fact, systemic relapse occurs within about 6–
9 months (Suzuki et al, 2005; Dalle et al, 2010). However,
the skin-directed therapeutic approach can be a reasonable
palliative option for elderly patients or those who are not eli-
gible for systemic intensive chemotherapy. Dalle et al (2010)
compared the outcome of patients with exclusive cutaneous
versus those with systemic involvement, showing no differ-
ence in terms of response and response duration. A more
recent study found that prognosis is invariably severe in both
presentations and systemic approaches are recommended
(Rauh et al, 2012).
Regarding the best induction regimen, retrospective stud-
ies suggest that treatment with regimens commonly used in
non-Hodgkin lymphoma yield complete remission (CR) rates
of 40-–50%, but responses are short lived (Kharfan-Dabaja
et al, 2013). Patients treated with regimens used in acute leu-
kaemia, particularly ALL-type regimens, seem to obtain bet-
ter responses (Reimer et al, 2003; Tsagarakis et al, 2010).
Feuillard et al (2002) reported the outcome of 23 patients
treated with different chemotherapy regimens. CR was
obtained in 86% of patients with a median follow-up of
15 months; however 83% of patients who obtained CR
relapsed, and the median time of relapse was 9 months (range
3–18 months). The chemotherapy provided a high response
rate, regardless of the type of regimen applied, but relapse was
very frequent and rapid, suggesting the need for an intensive
consolidation treatment (Feuillard et al, 2002). More recently,
the Hellenic Group described 22 patients, of whom 19 were
treated with different regimens: 474% received ALL-type ther-
apy, 316% AML-type therapy and 21% lymphoma-type ther-
apy (Tsagarakis et al, 2010). The median follow-up time was
15 months (range 66–234 months). A CR was reached in
789% of cases, 40% of who relapsed with an OS of 432% at
2 years. A relative superiority of ALL-type regimens was
reported in terms of response and response duration (Tsagara-
kis et al, 2010). Moreover, Pemmaraju et al (2012) reported a
CR of 90% in 10 patients treated with hyper-CVAD (hyper-
fractionated cyclophosphamide, vincristine, adriamycin, and
dexamethasone/methotrexate, cytarabine), with a median
duration of response of 19 months (range 4–39) and an OS of
29 months (range 1–44).
The largest study investigating treatment was a retrospective
analysis of 43 patients diagnosed with BPDCN after a central-
ized histological revision at 28 Italian divisions (Pagano et al,
2013). The median OS was 87 months with estimated survival
rates of 28% and 7% at 12 and 24 months, respectively. Forty-
one patients received an induction therapy with an acute leu-
kaemia-like regimen, consisting of AML-type therapy in 26
cases (60%) and ALL/lymphoma-type therapy in 15 (35%).
Seventeen patients (41%) achieved a CR, 7 after AML-type
regimens and 10 after ALL/lymphoma-type regimens, with a
significant advantage for the ALL-type approach. However, six
patients (35%) of the patients who achieved CR subsequently
relapsed, at a median time of 91 months (range 58–198)
after diagnosis (Pagano et al, 2013).
Finally, Martın-Martın et al (2015) recently described 25
patients aggressively-treated with intensive chemotherapy
[ALL-type therapy (7/25), AML-type therapy (9/25) and lym-
phoma-type therapy (9/25)] and showed that cases treated
with ALL-type protocols had a better outcome than the other
patients, with lower rates of relapse and overall mortality.
The major studies reporting induction therapy in BPDCN
that have included at least four patients are summarized in
Table IV. No conclusive data concerning the best induction
regimen can be drawn, even if ALL-type therapies appear
more effective in many reports. It is also interesting to note
that L-asparaginase and methotrexate, two drugs commonly
used in ALL treatment, were reported to be active in some
Review
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experiences (Gilis et al, 2012; Gruson et al, 2013). Recently,
preclinical studies by the French national network on
BPDCN have shown that BPDCN cells are sensitive in vitro
to idarubicin: culture with a combination of idarubicin,
methotrexate, L-asparaginase and dexamethasone resulted in
a synergistic effect because the viability of BPDCN primary
cells decreased from 47  75% to 61  14% (n = 5)
(Angelot-Delettre et al, 2015). The authors studied nine
patients receiving idarubicin in first-line therapy, obtaining a
CR in seven cases and only one relapse after 10 months of
response to therapy. However, the six patients in continuous
CR without any relapse have been transplanted.
Conventional chemotherapy alone does not appear to be
sufficient to ensure durable long-term remissions, with a
relapse rate of about 60% of patients achieving a CR. The
potential role of maintenance therapy deserves investigation
in BPDCN.
CNS prophylaxis
As previously reported, CNS involvement has been observed
both at presentation (Feng et al, 2014; Saeed et al, 2014)
and, more often, during disease recurrence (Feuillard et al,
2002; Pagano et al, 2013). The outcome of three of the six
patients who relapsed after achieving CR with a CNS
involvement was reported by Pagano et al (2013); none of
these patients had received intrathecal prophylaxis. From
these observations, CNS prophylaxis, with intrathecal drug
infusion of cytarabine or other drugs able to pass the blood-
brain barrier, is strongly suggested in all patients, and must
be routinely incorporated into induction treatment.
Haematopoietic stem cell transplantation (HSCT)
While the majority of adult patients with BPDCN will
achieve a complete or partial response to induction therapy,
most will relapse within two years, irrespective of the type of
chemotherapy received (Table III). There are no published
randomized controlled trials evaluating the role of autolo-
gous or allogeneic HSCT in patients with BPDCN, and most
available information is derived from retrospective case
reports and single-institution experiences on a limited num-
ber of patients, which, as such, suffer from several limita-
tions. The little evidence provided by previous studies
Table IV. Results of the main published studies reporting high-dose chemotherapy and haematopoietic stem cell transplantation in BPDCN (se-
lected studies with at least four cases). The highest percentage of patients alive in CR was observed after allogeneic HSCT in first CR.
References
Median age,
years (range)
Transplantation
procedure
Patients
(n)
Outcome
(alive in CR) n (%)
Median OS,
months (range)
Reimer et al (2003) 285 (23–51) Auto-HSCT in CR1 3 1 (25) 165 (n.r.)
Auto-HSCT > CR1 or no CR 1
28 (6–35) Allo-HSCT in CR1 4* 3 (43) 385 (n.r.)
Allo-HSCT > CR1 3*
Suzuki et al (2005) 355 (14–61) Auto-HSCT in CR1 2 n.r. 135 (6–37)
Auto-HSCT > CR1 or no CR 4
Dalle et al (2010) 25 Auto-HSCT > CR1 or no CR 1 1 (100) 21 (12–77)
38 (25–67) Allo-HSCT in CR1 4* 3 (75)
Allo-HSCT > CR1 6* 2 (33)
Dietrich et al (2011) 66 (56–70) Allo-HSCT in CR1 1† 1 (100) 19 (n.r.)
Allo-HSCT > CR1 3† 1 (33) 25 (23–82)
Tsagarakis et al (2010) n.r. Allo-HSCT in CR1 5‡ 3 (60) 15 (66–234)
Pagano et al (2013) n.r. Allo-HSCT in CR1 3* 2 (67) 227 (12–329)
Allo-HSCT > CR1 or no CR 3* 0 –
Roos-Weil et al (2013) 41 (10–70) Allo-HSCT in CR1 19§ 16 (47) 28 (4–77)
Allo-HSCT > CR1 15§
Unteregger et al (2013) 59 (38–64) Allo-HSCT in CR1 3† 3 (100) 21 (18–30)
Allo-HSCT > CR1 or no CR 2† 1 (50) 295 (20–39)
Heinicke et al (2015) 62 (22–66) Allo-HSCT in CR1 2 (1*, 1†) 2 (100) 265 (18–35)
Allo-HSCT > CR1 1 (1†) 1 (100) 41 (n.r.)
Aoki et al (2015) 57 (19–67) Auto-HSCT in CR1 11 n.r. 535 (n.r)
58 (17–64) Allo-HSCT in CR1 10 (5*, 5†)
Allo-HSCT > CR1 or no CR 4 (3*, 1†)
Auto-HSCT, autologous haematopoietic stem cell transplantation; allo-HSCT, allogeneic haematopoietic stem cell transplantation; CR, complete
remission; CR1, first complete remission; OS, overall survival; n.r., not reported.
*Myeloablative conditioning (MAC).
†Reduced-intensity conditioning (RIC).
‡Type of conditioning not reported.
§Overall 25 MAC and 9 RIC.
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suggests that the clinical course and the response to therapy
differ between children and adults (Feuillard et al, 2002;
Dalle et al, 2010; Jegalian et al, 2010; Hashikawa et al, 2012).
BPDCN occurring in childhood is clinically less aggressive,
and children (<18 years) appear to benefit from treatment
similar to that given for high-risk ALL, reserving allogeneic
HSCT for patients who relapse and achieve a second CR
(Jegalian et al, 2010). On the contrary, as the disease is more
aggressive in adults, there is emerging evidence suggesting
that adults may benefit from allogeneic HSCT in first CR,
achieving long-term survival (Dietrich et al, 2011; Pagano
et al, 2013; Roos-Weil et al, 2013). Adults with comorbidities
may be considered for reduced intensity conditioning. The
role of autologous HSCT is still debated.
The response rates and survival of patients undergoing
autologous and allogeneic HSCT in the main studies are
reported in Table IV.
Autologous HSCT
Few cases of autologous HSCT are available in literature
(Table IV). Reimer et al (2003) described four patients
receiving autologous HSCT; only one of them obtained a
CR, with a median survival of 13 months. Suzuki et al
(2005) reported the experience of autologous HSCT per-
formed in six patients: three were alive and in CR after 11,
22 and 37 months, respectively. Other single cases of success-
ful treatment with autologous HSCT have been reported
(Dalle et al, 2010; Goren Sahin et al, 2013).
Recently, Aoki et al (2015) demonstrated, for the first
time, the clinical advantage of performing autologous HSCT
in first CR on a reasonably large number of BPDCN. The
authors reported the outcome of 11 patients (median age
57 years, range 19–67) from registry data of the Japan Soci-
ety for Haematopoietic Cell Transplantation: all of them
underwent autologous HSCT in first CR and, after a median
follow-up of 535 months, they achieved an advantage both
on OS (4 year-OS 82%) and on progression free survival (4-
year PFS 73%), regardless of the type of induction regimen.
This is the largest study to analyse the role of autologous
HSCT in BPDCN, suggesting that high-dose chemotherapy
may play an important role in curing BPDCN independent
of a graft-versus-tumour effect of allogeneic HSCT and that
the disease status at autologous HSCT is crucial for a better
outcome (Aoki et al, 2015).
The small number of published studies precludes the iden-
tification of a particular subset of BPDCN likely to benefit
from high-dose therapy and autologous HSCT. It appears,
however, that patients with active and chemorefractory dis-
ease are not likely to achieve durable remissions after autolo-
gous HSCT (Reimer et al, 2003; Aoki et al, 2015). These
cases should ideally be considered for enrolment in clinical
trials, while autologous HSCT might be offered to patients
with chemosensitive disease, preferably early in the disease
course, and to older patients in good clinical condition.
Finally, considering the great heterogeneity of conditioning
regimens employed in autologous HSCT, the limited number
of treated patients and the variations in survival reported in
the few published studies, it is difficult to recommend a
specific high-dose regimen before autologous transplantation.
However, bearing in mind the high rate of CNS involvement
both at diagnosis and above all at relapse, thiotepa-based
conditioning regimens should be preferred to standard lym-
phoma regimens, given the appreciable blood-brain barrier
penetration of thiotepa and its active metabolite tepa, also
used in the treatment of high-grade lymphoid malignancies
(Heideman et al, 1989; Ferreri et al, 2008).
Allogeneic HSCT
Data regarding the outcomes following allogeneic HSCT
come from retrospective analyses of small series of patients
and single case reports showing that myeloablative treatment
with allogeneic HSCT during the first remission resulted in
the chance of a significant improvement of survival, espe-
cially in young patients (Feuillard et al, 2002; Reimer et al,
2003; Tsagarakis et al, 2010) (Table IV). Reimer et al (2003)
described four patients treated with allogeneic HSCT in first
CR, three of who remained in CR at the time of reporting.
Three more patients received allogeneic HSCT in second or
subsequent remission and all of them died from disease
recurrence or toxicity (Reimer et al, 2003).
In the French analysis (Dalle et al, 2010), 10 of the 47
patients with BPDCN were transplanted during the manage-
ment of the disease (nine allogeneic transplants, one autolo-
gous transplant, median age 38 years); the transplanted
patients had a significantly longer survival (313 months)
than that of the non-transplanted patients (12 months)
(Dalle et al, 2010). Dietrich et al (2011) demonstrated the
feasibility of allogeneic HSCT in older patients with the use
of a reduced intensity conditioning regimen. They described
four patients (median age 67 years) who underwent allo-
geneic HSCT, of which two were allografted in remission
and were alive and disease-free at 57 and 16 months post-
transplant. Interestingly, one of the patients in CR suffered
from extensive chronic graft-versus-host-disease (GVHD),
which suggests a clinically significant graft-versus-leukaemia
(GVL) effect operating in BPDCN (Dietrich et al, 2011).
The European Group for Blood and Marrow Transplanta-
tion have performed the largest retrospective study, analysing
34 patients with a median age of 41 years, receiving allo-
geneic HSCT from sibling (n = 11) or unrelated donors
(n = 23). Myeloablative conditioning (MAC) was used in 25
(74%) patients. Nineteen patients (56%) were transplanted
in first CR. The 3-year cumulative incidence of relapse, dis-
ease-free survival (DFS) and OS was 32%, 33% and 41%,
respectively (Roos-Weil et al, 2013). Univariate analysis indi-
cated that receiving a transplant in first CR was associated
with a significantly favourable outcome, whereas age, donor
source and presence of chronic GVHD had no impact on
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survival. Noteworthy, analysing only the patients who under-
went MAC in first CR, produced a three-year DFS of 45%
and an OS of 60%. No relapses were observed after
27 months post-HSCT, suggesting that high-dose therapy
followed by allogeneic HSCT can provide durable disease
control even in elderly patients with BPDCN. It remains to
be shown if the efficacy of allogeneic HSCT can be attributed
to an eventual graft-versus-leukaemia effect or if is just a
matter of high-dose intensity conferred with MAC regimens
(Roos-Weil et al, 2013). In this study, having chronic GVHD
was not associated with improved disease control. However,
the reduced-intensity conditioning (RIC) group comprised
only nine patients, and failure in this group of patients was
mainly due to non-relapse mortality rather than relapse.
Therefore, the contribution of the GVL effect and the role of
RIC allogeneic HSCT cannot be defined based on this study
(Roos-Weil et al, 2013).
Interestingly, two groups have recently presented strong
evidence for the existence of a potent GVL effect in BPDCN
(Kaloyannidis et al, 2010; Unteregger et al, 2013). Kaloyanni-
dis et al (2010) reported a BPDCN patient whose relapse,
26 months after allogeneic HSCT while on prolonged
immunosuppression, was successfully treated with donor-
lymphocyte infusions combined with injections of inter-
leukin-2 and interferon alpha (Kaloyannidis et al, 2010).
Unteregger et al (2013) treated five patients with allogeneic
HSCT during the first or subsequent remission. Two patients
received RIC, 1 MAC and 2 umbilical cord blood (UCB)
transplantations. No GVHD was observed in patients who
received UCB HSCT, but both of these patients developed
post-transplantation lymphoproliferative disease. Four
patients were in CR at the time of the report, with PFS and
OS rates of 17 and 21 months, respectively. One experienced
relapse; in this patient, a strong GVL effect was induced by
four escalating doses of donor lymphocyte infusions leading
to a second CR (Unteregger et al, 2013). Thus, it is likely
that this GVL effect may substantially contribute to the suc-
cess of allogeneic HSCT in BPDCN patients. Regarding the
use of cord blood stem cells, Ramanathan et al (2013)
described the case of BPDCN onset in a young woman as a
leukaemia who successfully underwent UCB HSCT in first
CR. The authors demonstrated for the first time that UCB
HSCT could be a feasible and effective therapeutic strategy
for this rare and aggressive leukaemia. The advantages of
using UCB as source of stem cells include, among others, the
increased ability to find a donor and the reduced incidence
of life threatening grade 3 or 4 acute GVHD (Ramanathan
et al, 2013).
Finally, Heinicke et al (2015) reported three patients that
were treated with acute leukaemia-type induction therapy
followed by allogeneic HSCT (one after standard MAC and
two after RIC) who achieved sustained remissions with a fol-
low-up of 8, 35 and 41 months, respectively, whereas median
survival in the non-allogeneic HSCT group was only
95 months and only one patient survived beyond 1 year.
Lokare et al (2014) reported a patient treated with alem-
tuzumab-based T cell-deplete conditioned allogeneic trans-
plant, who is currently alive and in remission 4 years post-
transplant.
The encouraging results reported above suggest that allo-
geneic HSCT may result in prolonged remissions and repre-
sents the best therapeutic choice, especially in younger
patients achieving a CR, who comprise the minority of cases.
RIC regimens should be considered for patients in CR who
are not fit to undergo myeloablative transplantation due to
advanced age or medical comorbidities.
Notably, interpreting the beneficial role of allogeneic
HSCT in this aggressive neoplasm, the possibility of inherent
biases must be taken in account. First of all, allogeneic trans-
plantation may appear superior just by virtue of patient
selection, as the efficacy of this procedure has been always
reported in younger patients in CR, who represent a better
population from a biological point of view (selection bias in
relation to age). In addition, the small number of published
cases may suggest the existence of a reporting bias.
Ultimately, collaborative prospective clinical trials are
needed to thoroughly define the role of allogeneic HSCT in
BPDCN.
Palliative therapy
Few data are available for the management of older patients
or relapsed patients unfit for HSCT. Hatano et al (2007)
described a 72-year-old patient treated with low-dose etopo-
side oral therapy, obtaining a long-term remission after iso-
lated cutaneous relapse. A single report of Pralatrexate in
relapsed BDPCN with skin lesions suggests a possible role for
this agent. Pralatrexate shows greater antitumour effects, with
particular activity in methotrexate-resistant T-cell lymphomas
and in cutaneous lymphomas. The authors described a dur-
able response in an elderly patient with prevalent skin disease
resistant to CHOP (cyclophosphamide, doxorubicin, vin-
cristine, prednisolone) treatment. This encouraging experi-
ence should be confirmed with further studies (Leitenberger
et al, 2008). It is conceivable that less intensive regimens and
monochemotherapy may be used in relapsed elderly patients
that are not eligible for HSCT.
On the contrary, for those elderly patients with a low per-
formance status or characterized by the presence of relevant
co-morbidities (i.e., cardiopathy, chronic obstructive pul-
monary disease) the best supportive care is the only option
that must be considered.
Future perspectives and new targeted drugs
No targeted agents are currently approved for patients with
BPDCN, even if the results of early clinical studies have
revealed novel targets and potentially effective agents.
Agliano et al (2011) developed a xenograft mouse model
of human BPDCN, on which the effect of lenalidomide was
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tested. The drug showed a relevant cytotoxic and proapop-
totic activity on the murine model, which was also supported
by molecular analysis of cytokine levels and enzymatic activ-
ity; however these data have not been confirmed clinically
(Agliano et al, 2011).
Another promising potential therapeutic option comes
from a recent analysis of gene expression profile which dis-
covered aberrant activation of the NF-kB pathway, indicating
it as a suitable therapeutic target (Sapienza et al, 2014).
Moreover, the authors showed that the BPDCN cell line,
CAL-1, was highly sensitive to bortezomib treatment both in
terms of proliferation inhibition and cell death induction
(Sapienza et al, 2014).
The recently discovery of recurrent mutations of genes
involved in DNA methylation, mainly TET2 and IDH1/2
(Alayed et al, 2013; Menezes et al, 2014; Rakheja et al, 2015)
provide a strong rationale for the use of epigenetic therapies
for BPDCN treatment. A clear and sustained activity on skin
lesions and systemic manifestation of BPDCN has been
recently reported in two elderly patients, who underwent
frontline therapy with 5-azacytidine and achieved resolution
of their skin lesions and stabilization of their haematological
parameters (Laribi et al, 2014).
In addition, Pagano et al (2013) described three cases of
BDPCN with FLT3-ITD mutations, suggesting a potential
role of FMS-like tyrosine kinase-3 inhibitors.
Among the new drugs, the most promising is SL-401, a
recombinant human interleukin 3a (IL3A) protein conju-
gated with truncated diphtheria a-toxin, a potent inhibitor
of protein synthesis (Frankel et al, 2000, 2014; FitzGerald,
2014; Angelot-Delettre et al, 2015). The IL3 receptor (IL3R)
is a heterodimer combining an a chain (CD123) and a b
chain (CD131); CD123 is highly expressed in BPDCN. The
binding of SL-401 with IL3R causes the internalization and,
consequently, the translocation of the diphtheria toxin into
the cytosol that binds to ADP-ribosylated elongation factor
2, leading to inactivation of protein synthesis and cell
death. The cytotoxicity of SL-401 was assessed in a preclini-
cal study in patient-derived BPDCN cell lines (CAL-1 and
GEN22). This compound exhibited a strong cytotoxicity in
a dose dependent and more efficient way than other tested
chemotherapeutic drugs. Mice inoculated with a BPDCN
cell line and treated with a single cycle of SL-401 survived
significantly longer than untreated controls (Angelot-Delet-
tre et al, 2015). Frankel et al (2014) reported data from a
phase 1/2 study in which 11 patients (7 relapsed and 4
untreated) with BPDCN received a single daily course of
SL-401 at 125 lg/kg for 5 d. Seven of the 9 BPDCN
patients evaluable for response had objective responses
(78%, 5 CR and 2 PR). The median duration of response
was 5 months. Grade 3 or 4 toxicities observed were
thrombocytopenia, neutropenia, transaminase elevations,
hypoalbuminaemia and hyponatraemia. Fever, chills and
nausea were usually experienced within the first several
hours after infusion, mitigated by premedication. All
adverse events were brief and resolved completely and no
treatment-related deaths were observed (Frankel et al,
2014). Recently, the lead-in stage results of a pivotal trial
on the use of SL-401 in 9 patients with relapsed/refractory
BPDCN have been published (Sweet et al, 2015). Five
(71%) of 7 evaluable BPDCN patients had major objective
responses, including CR with normalization to ≤5% blasts
in the bone marrow involvement in 4 patients. The resolu-
tion of extensive symptomatic skin lesions, lymphadenopa-
thy and soft tissue disease has also been noted, often within
days of starting treatment with an acceptable safety profile
(Sweet et al, 2015).
These encouraging results suggest that target therapy has
the potential for improving patient outcomes. SL-401 could
be used to consolidate the effects of first-line chemotherapy
and/or to reduce minimal residual disease before allogeneic
HSCT. An on-going prospective study is expected to confirm
these results (NCT02113982).
Conclusions
BPDCN is a rare disease, with a dismal prognosis, behaving
like acute leukaemia with high-risk features, and arising from
precursors of plasmacytoid dendritic cells. Accurate diagno-
sis, which requires expert physicians, both clinicians and
histopathologists, is essential in order to provide prompt
treatment, especially considering that the clinical presentation
is often indolent. BPDCN may be suspected from a set of
converging features from the clinical presentation to histo-
logical findings, but overlap with other haematological neo-
plasms is considerable. The final diagnosis relies on a
compatible immunophenotype, which must be confirmed by
accurate immunohistochemical and cytofluorimetric analysis
with extended panels. The tumour cells typically express CD4
and CD56, combined with the expression of one or more
plasmacytoid dendritic cell specific antigens (CD123, BDCA-
2/CD303, TCL1, CTLA1 [also termed GZMB]). There are
few data regarding the best treatment, which remains to be
defined. Moreover, clinical practise generally varies based on
institutional preference. Similarly to Riaz et al (2014), we
suggest a tailored therapeutic approach according to the age
and the clinical condition of the patients (Fig 1). While
patients aged >75 years or >65 with medical comorbidities
can be treated with low dose monochemotherapy in order to
resolve the disease, for adults <65 years and/or without
comorbidities with newly diagnosed BPDCN, we suggest
induction chemotherapy with a regimen similar to that used
for ALL treatment, including intrathecal prophylaxis. On the
other hand, due to the relatively short-lived remissions after
frontline therapies and the myeloid lineage derivation of
blastic dendritic cells, accordingly to our previous experience
(Pagano et al, 2013), we suggest the addition of more mye-
loid-focussed strategies, such as consolidation with high or
intermediate doses of cytarabine, which represents the back-
bone of therapy for AML (L€owenberg et al, 2011; B€uchner
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et al, 2012) and could be useful for reducing minimal resid-
ual disease, even if no data exist about this therapeutic possi-
bility in BPDCN. Given that effective second-line therapies
remain elusive, for adults who achieve a CR, we recommend
allogeneic HSCT in first remission; adults in CR who are not
candidates for myeloablative HSCT may be considered for
RIC. Autologous HSCT may be reserved for patients who are
not eligible for allogeneic procedures or if a suitable donor is
not available, as ‘consolidation’ therapy, early in the disease
course. A valid therapeutic approach can be to offer a patient
enrolment into a well-designed, scientifically valid clinical
trial (Fig 1).
Future new insights for such a rare and severe disease can
only derive from cooperative, eventually prospective, studies.
For elderly or unfit patients, considering the high probability
of early relapse even after a successful induction, the role of
a maintenance treatment needs to be explored. Preclinical
studies support the efficacy of lenalidomide, a drug success-
fully used as maintenance in other diseases. From other pre-
clinical studies a possible role for other agents active in dis-
eases with aberrant NF-KB activation, as well as epigenetic
treatments could be explored. At the present time, the only
really promising new agent has been elegantly created, conju-
gating IL3 to diphtheria toxin; very encouraging results have
been obtained with this drug in pre-treated patients, a group
with very bad prognosis in this disease. Special and coopera-
tive efforts should be made for continuing the evaluation of
this drug earlier in the course of the disease or in combina-
tion with other agents.
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